Our data indicated that magnolol combined with regorafenib downregulated the protein level of MDC-1, compared to the treatments with magnolol or regorafenib alone, in HCC in vitro and in vivo (Figure 1G,H and Figure 6I). This evidence concerns the gene MDC1 and hepatocellular carcinoma.